Clinical trials: Erlotinib
Non-small Cell Lung Cancer
Evaluate Erlotinib Efficacy and Safety as the 2nd/3rd Treatment in NSCLC With EGFR M(-) and C-met(-)
evaluate Erlotinib efficacy and safety as the 2nd/3rd line treatment in advanced or recurrent NSCLC with EGFR wild type and without c-met expression
- Trial name
- NCT02006043
- Testing
- Erlotinib 150mg
- Where
- 2 sites in China
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Li Zhang
Non-Small-Cell Lung Carcinoma
Study of OSI-774 (Tarceva) in Previously Untreated Elderly Lung Cancer Patients
The primary purpose of this study is to determine whether the drug OSI-774 is less toxic and potentially as good as or better than standard chemotherapy drugs, when given to subjects with non-small cell lung cancer, who are 70…
- Trial name
- NCT00137800
- Testing
- OSI-774 (Tarceva)
- Where
- 2 sites in United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Dana-Farber Cancer Institute
Lung Cancer
A Single-Dose,ComparativeBioavailability Study ofTwo Formulations ofErlotinib150mgTabletsunderFastingConditions
Theobjectiveofthisstudyistoevaluatethecomparativebioavailabilitybetween: ErlotinibHCl150mgTablets(Novopharm Limited,Canada)and Tarceva® 150mgTablets(Hoffmann-LaRocheLimited,Canada)…
- Trial name
- NCT04145570
- Testing
- Erlotinib HCl 150 mg, Tarceva®
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Quadras Scientific Solutions
Glioblastoma Multiforme, Anaplastic Astrocytoma
Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma
This study will offer a safe treatment for patients with relapsing recurring glioblastoma (GBM) or anaplastic astrocytoma (AA). The trial will test the hypothesis that Erlotinib (Tarceva, OSI-774) can be safely used up to a dose…
- Trial name
- NCT00301418
- Testing
- Erlotinib
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Northwell Health
Prostate Cancer
Single Agent Erlotinib in Chemotherapy-naive Androgen Independent Prostate Cancer
Objectives to evaluate the activity of Erlotinib in prostate cancer patients who are hormone refractory and androgen independent and have not been exposed to chemotherapy.
- Trial name
- NCT00272038
- Testing
- Tarceva
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Oncology Specialists, S.C.
Multiple Brain Metastases, Non-small-cell Lung Cancer
Phase Ⅲ Trial of WBRT Versus Erlotinib Concurrent Whole-brain Radiation Therapy as first-line Treatment for Patients With Multiple Brain Metastases From Non-small-cell Lung Cancer(ENTER): a Multicentre, Open-label, Randomised Study
1. Verify the effect of Erlotinib concurrent whole-brain radiation therapy as first-line treatment for patients with multiple brain metastases from non-small-cell lung cancer to compare with WBRT alone. 2.
- Trial name
- NCT01887795
- Testing
- Erlotinib, WBRT
- Where
- China
- Volunteers
- 224 people, healthy volunteers welcome
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Prostate Cancer
Study of Erlotinib in Patients With Non-Metastatic Prostate Cancer With a Rising Prostate Specific Antigen (PSA) on Hormone Therapy
The primary objective of this study is to evaluate the effect of erlotinib on the PSA response rate in patients with non-metastatic prostate cancer and a rising PSA on androgen deprivation therapy.
- Trial name
- NCT00148772
- Testing
- Erlotinib (Tarceva)
- Where
- 2 sites in United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Endeavor Health